Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
McKinsey
Harvard Business School
Medtronic
AstraZeneca

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022517

See Plans and Pricing

« Back to Dashboard

NDA 022517 describes NOCDURNA, which is a drug marketed by Ferring Pharms Inc and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug. Additional details are available on the NOCDURNA profile page.

The generic ingredient in NOCDURNA is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.
Summary for 022517
Tradename:NOCDURNA
Applicant:Ferring Pharms Inc
Ingredient:desmopressin acetate
Patents:9
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 022517
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517 NDA Ferring Pharmaceuticals Inc. 55566-5050 55566-5050-1 3 BLISTER PACK in 1 CARTON (55566-5050-1) > 10 TABLET in 1 BLISTER PACK (55566-5050-0)
NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517 NDA Ferring Pharmaceuticals Inc. 55566-5070 55566-5070-1 3 BLISTER PACK in 1 CARTON (55566-5070-1) > 10 TABLET in 1 BLISTER PACK (55566-5070-0)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;SUBLINGUALStrength0.0277MG
Approval Date:Jun 21, 2018TE:RLD:Yes
Regulatory Exclusivity Expiration:Jun 21, 2021
Regulatory Exclusivity Use:NEW PRODUCT
Patent:  Start TrialPatent Expiration:May 7, 2023Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Feb 2, 2024Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Baxter
Harvard Business School
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.